Dr. Jung-Im Shin, an assistant professor in the department of epidemiology at the Johns Hopkins Bloomberg School of Public Health, has received a $570,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to determine the utilization, comparative effectiveness, and safety of second-line therapy in people with type 2 diabetes.
Type 2 diabetes is associated with high levels of morbidity and mortality. Although consensus exists around metformin as the first-line pharmacologic therapy, great uncertainty remains regarding the optimal choice of a second-line therapy, with inconsistent recommendations across guidelines. Using real-world data, Dr. Shin’s study aims to evaluate five classes of second-line treatments after metformin (i.e., SGLT2 inhibitors, GLP1 receptor agonists, DPP4 inhibitors, thiazolidinediones, and sulfonylureas) with regard to effectiveness for hyperglycemia management, risks of adverse events, and benefits on long-term clinical outcomes.
Dr. Shin’s research is focused on improving the clinical care of patients afflicted by chronic disease, particularly those with diabetes, kidney, and cardiovascular disease, through thoughtful and rigorous pharmacoepidemiology research. The results of this project will provide evidence for knowledge gaps that underlie core clinical practice by a comprehensive assessment of the risks and benefits of second-line antidiabetes treatments, affecting approximately thirty million U.S. patients with type 2 diabetes.Tags: Friday Letter Submission, Publish on September 06